Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of ranibizumab and aflibercept and the effect of vitrectomy
2012-005500-18Phase 4Completed
- Sponsor
- King's College Hospital
- Start
- Nov 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of ranibizumab and aflibercept in age-related macular degeneration (AMD) (3 arms), sponsored by King's College Hospital. Primary endpoint: Half-life of intravitreal ranibizumab. Started Nov 2013; status: completed.
02
Drugs
ranibizumabaflibercept
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2012-005500-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005500-18.